Drugs / ASTX660
ASTX660
also known as
Tolinapant · 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one
Small molecule targets XIAP via inhibition
Trials 11
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASTX660 | “TOLINAPANT (ASTX660)” NCT05912075 ↗ |
| Known as | 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one | “A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1...” PMID 30091600 ↗ Aug 2018 |
| Known as | Tolinapant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06393751 ↗ |
| Action | Inhibit | “ASTX660 is a synthetic small molecule dual antagonist of cellular inhibitor of apoptosis protein (cIAP) 1 and X-linked inhibitor of apoptosis protein (XIAP)” NCT02503423 ↗ |
| Modality | Small molecule | “ASTX660 is a synthetic small molecule dual antagonist” NCT02503423 ↗ |
| Route | Oral | “Capsule for oral administration” NCT04155580 ↗ |
| Target | XIAP | “blocking proteins, such as XIAP and cIAP1, that promote the growth of tumor cells” NCT06393751 ↗ |